NASDAQ:ZYNE Zynerba Pharmaceuticals (ZYNE) Stock Forecast, Price & News $0.36 +0.03 (+9.09%) (As of 06/7/2023 ET) Add Compare Share Share Today's Range$0.34▼$0.3750-Day Range$0.30▼$0.4352-Week Range$0.30▼$1.60Volume195,801 shsAverage Volume258,194 shsMarket Capitalization$19.31 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Zynerba Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside2,955.6% Upside$11.00 Price TargetShort InterestHealthy0.16% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.78) to ($0.61) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.05 out of 5 starsMedical Sector455th out of 981 stocksPharmaceutical Preparations Industry206th out of 464 stocks 3.4 Analyst's Opinion Consensus RatingZynerba Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.00, Zynerba Pharmaceuticals has a forecasted upside of 2,955.6% from its current price of $0.36.Amount of Analyst CoverageZynerba Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.16% of the outstanding shares of Zynerba Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverZynerba Pharmaceuticals has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Zynerba Pharmaceuticals has recently decreased by 7.05%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldZynerba Pharmaceuticals does not currently pay a dividend.Dividend GrowthZynerba Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ZYNE. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 2 people have searched for ZYNE on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Zynerba Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -29% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zynerba Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders13.04% of the stock of Zynerba Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 23.82% of the stock of Zynerba Pharmaceuticals is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Zynerba Pharmaceuticals are expected to grow in the coming year, from ($0.78) to ($0.61) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zynerba Pharmaceuticals is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zynerba Pharmaceuticals is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZynerba Pharmaceuticals has a P/B Ratio of 0.36. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Zynerba Pharmaceuticals (NASDAQ:ZYNE) StockZynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on the research and development of rare and near-rare neuropsychiatric conditions. The firm offers the Zygel product, which is formulated as a permeation-enhanced gel for transdermal delivery. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.Read More Receive ZYNE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zynerba Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ZYNE Stock News HeadlinesMay 31, 2023 | americanbankingnews.comZynerba Pharmaceuticals (NASDAQ:ZYNE) Research Coverage Started at StockNews.comMay 24, 2023 | americanbankingnews.comZynerba Pharmaceuticals (NASDAQ:ZYNE) Now Covered by StockNews.comJune 7, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.May 23, 2023 | americanbankingnews.comFY2023 Earnings Forecast for Zynerba Pharmaceuticals, Inc. Issued By Cantor Fitzgerald (NASDAQ:ZYNE)May 17, 2023 | bizjournals.comMain Line CBD drug developer plans reverse stock split to boost share priceMay 17, 2023 | americanbankingnews.comZynerba Pharmaceuticals (NASDAQ:ZYNE) Issues Earnings ResultsMay 15, 2023 | finanznachrichten.deZynerba Pharmaceuticals, Inc.: Zynerba Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational HighlightsMay 15, 2023 | investing.comZynerba Pharma (ZYNE) Earnings Dates & ReportsJune 7, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!May 15, 2023 | msn.comZynerba Pharmaceuticals R&D Expenses For Q1 Reach $7.1M, Here Are The DetailsMay 15, 2023 | finance.yahoo.comZynerba Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational HighlightsMay 15, 2023 | finance.yahoo.comZynerba Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational HighlightsMay 15, 2023 | americanbankingnews.comZynerba Pharmaceuticals (NASDAQ:ZYNE) Receives New Coverage from Analysts at StockNews.comMay 13, 2023 | americanbankingnews.comZynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Short Interest Down 49.6% in AprilMay 7, 2023 | americanbankingnews.comZynerba Pharmaceuticals (NASDAQ:ZYNE) Now Covered by Analysts at StockNews.comApril 30, 2023 | americanbankingnews.comZynerba Pharmaceuticals (NASDAQ:ZYNE) Coverage Initiated at StockNews.comApril 18, 2023 | marketwatch.comFibromyalgia Treatment Drug Market Overview and Scope By 2030April 18, 2023 | americanbankingnews.comZynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Short Interest UpdateApril 14, 2023 | marketwatch.comZynerba Pharmaceuticals Presents Data on Zygel(TM) at the 55th Gatlinburg ConferenceApril 13, 2023 | americanbankingnews.comStockNews.com Begins Coverage on Zynerba Pharmaceuticals (NASDAQ:ZYNE)April 12, 2023 | finance.yahoo.comZynerba Pharmaceuticals Presents Data on Zygel™ at the 55th Gatlinburg ConferenceApril 5, 2023 | finance.yahoo.comZynerba Pharmaceuticals Announces Poster Presentations at the 55th Gatlinburg ConferenceApril 4, 2023 | americanbankingnews.comQ1 2023 EPS Estimates for Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Boosted by Jefferies Financial GroupMarch 31, 2023 | americanbankingnews.comZynerba Pharmaceuticals (NASDAQ:ZYNE) Announces Earnings ResultsMarch 31, 2023 | americanbankingnews.comZynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) to Post Q1 2024 Earnings of ($0.22) Per Share, Jefferies Financial Group ForecastsMarch 30, 2023 | americanbankingnews.comZynerba Pharmaceuticals (NASDAQ:ZYNE) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPSMarch 28, 2023 | finanznachrichten.deZynerba Pharmaceuticals, Inc.: Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational HighlightsSee More Headlines ZYNE Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ZYNE Company Calendar Last Earnings5/15/2023Today6/07/2023Next Earnings (Estimated)8/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ZYNE CUSIPN/A CIK1621443 Webwww.zynerba.com Phone(484) 581-7505FaxN/AEmployees28Year FoundedN/APrice Target and Rating Average Stock Price Forecast$11.00 High Stock Price Forecast$11.00 Low Stock Price Forecast$11.00 Forecasted Upside/Downside+2,955.6%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,040,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-75.12% Return on Assets-62.79% Debt Debt-to-Equity RatioN/A Current Ratio4.95 Quick Ratio4.95 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.01 per share Price / Book0.36Miscellaneous Outstanding Shares53,650,000Free Float46,656,000Market Cap$19.31 million OptionableOptionable Beta1.73 Key ExecutivesArmando AnidoChairman & Chief Executive OfficerTerri B. SebreePresidentJames E. FickenscherChief Financial Officer & VP-Corporate DevelopmentNancy TichVice President-ClinicalStephen O'QuinnVice President-Medical AffairsKey CompetitorsOncternal TherapeuticsNASDAQ:ONCTHumanigenNASDAQ:HGENEdesa BiotechNASDAQ:EDSAKazia TherapeuticsNASDAQ:KZIAPaxMedicaNASDAQ:PXMDView All CompetitorsInsiders & InstitutionsTwo Sigma Advisers LPSold 41,100 shares on 5/15/2023Ownership: 0.270%Renaissance Technologies LLCSold 270,800 shares on 5/12/2023Ownership: 1.062%ETF Managers Group LLCSold 787,721 shares on 4/18/2023Ownership: 1.355%ETF Managers Group LLCSold 748,098 shares on 3/23/2023Ownership: 3.302%Armando AnidoSold 35,453 sharesTotal: $21,271.80 ($0.60/share)View All Insider TransactionsView All Institutional Transactions ZYNE Stock - Frequently Asked Questions Should I buy or sell Zynerba Pharmaceuticals stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zynerba Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ZYNE shares. View ZYNE analyst ratings or view top-rated stocks. What is Zynerba Pharmaceuticals' stock price forecast for 2023? 4 brokerages have issued 12 month price objectives for Zynerba Pharmaceuticals' shares. Their ZYNE share price forecasts range from $11.00 to $11.00. On average, they predict the company's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 2,955.6% from the stock's current price. View analysts price targets for ZYNE or view top-rated stocks among Wall Street analysts. How have ZYNE shares performed in 2023? Zynerba Pharmaceuticals' stock was trading at $0.53 at the start of the year. Since then, ZYNE stock has decreased by 32.1% and is now trading at $0.36. View the best growth stocks for 2023 here. When is Zynerba Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023. View our ZYNE earnings forecast. How were Zynerba Pharmaceuticals' earnings last quarter? Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) issued its quarterly earnings data on Monday, May, 15th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.02. What ETFs hold Zynerba Pharmaceuticals' stock? ETFs with the largest weight of Zynerba Pharmaceuticals (NASDAQ:ZYNE) stock in their portfolio include Amplify Seymour Cannabis ETF (CNBS).ETFMG Alternative Harvest ETF (MJ). What other stocks do shareholders of Zynerba Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Zynerba Pharmaceuticals investors own include Cara Therapeutics (CARA), GW Pharmaceuticals (GWPH), Cronos Group (CRON), Aurora Cannabis (ACB), NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Shopify (SHOP) and Micron Technology (MU). When did Zynerba Pharmaceuticals IPO? (ZYNE) raised $42 million in an IPO on Wednesday, August 5th 2015. The company issued 3,000,000 shares at a price of $13.00-$15.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers. What is Zynerba Pharmaceuticals' stock symbol? Zynerba Pharmaceuticals trades on the NASDAQ under the ticker symbol "ZYNE." Who are Zynerba Pharmaceuticals' major shareholders? Zynerba Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include ETF Managers Group LLC (1.36%), Renaissance Technologies LLC (1.06%) and Two Sigma Advisers LP (0.27%). Insiders that own company stock include Armando Anido, Brian Rosenberger, Daniel L Kisner, James E Fickenscher and Terri B Sebree. View institutional ownership trends. How do I buy shares of Zynerba Pharmaceuticals? Shares of ZYNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Zynerba Pharmaceuticals' stock price today? One share of ZYNE stock can currently be purchased for approximately $0.36. How much money does Zynerba Pharmaceuticals make? Zynerba Pharmaceuticals (NASDAQ:ZYNE) has a market capitalization of $19.31 million. The company earns $-35,040,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis. How can I contact Zynerba Pharmaceuticals? Zynerba Pharmaceuticals' mailing address is 80 W. LANCASTER AVENUE SUITE 300, DEVON PA, 19333. The official website for the company is www.zynerba.com. The company can be reached via phone at (484) 581-7505 or via email at investorrelations@zynerba.com. This page (NASDAQ:ZYNE) was last updated on 6/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zynerba Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.